Rachelle Suzanne Jacques is Chief Executive Officer of Akari Therapeutics Plc. Currently has a direct ownership of 1.02 Billion shares of AKTX, which is worth approximately $1.02 Billion. The most recent transaction as insider was on Apr 26, 2024, when has been sold 479,569,892 shares (Ordinary shares, par value $0.0001 per share) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.02B
0% 3M change
n/a 12M change
Total Value Held $1.02 Billion

Rachelle Suzanne Jacques Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 26 2024
BUY
Grant, award, or other acquisition
-
479,569,892 Added 32.02%
1,018,027,792 Ordinary shares, par v...

Also insider at

VIE
Viela Bio, Inc.
CRBP
Corbus Pharmaceuticals Holdings, Inc. Healthcare
QURE
uniQure N.V. Healthcare
RSJ

Rachelle Suzanne Jacques

Chief Executive Officer
Amsterdam, P7

Track Institutional and Insider Activities on AKTX

Follow Akari Therapeutics Plc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKTX shares.

Notify only if

Insider Trading

Get notified when an Akari Therapeutics PLC insider buys or sells AKTX shares.

Notify only if

News

Receive news related to Akari Therapeutics Plc

Track Activities on AKTX